Lupus nephritis
Jan 27, 2023
Lupus Nephritis: A SILENT but SEVERE Systemic Lupus Erythematosus Manifestation
Lupus Nephritis (LN) is the most feared and common complication of systemic lupus erythematosus (SLE) and is responsible for the major share of morbidity and mortality of this disease. It affects around half of the systemic lupus erythematosus patients, and in ~35% of patients, lupus nephritis is the presenting fea...
Read More...
Jan 26, 2021
Aurinia’s Lupkynis for Lupus; FDA Fast Track Designation for Toripalimab; Wren Therapeutics’ Financing; Merck’s Covid-19 Vaccine Program End
Hot on the heels, Aurinia launches its drug in the Lupus market after GSK Aurinia Pharmaceuticals has recently got the USFDA approval for its Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active Lupus nephritis (LN). Lupkynis is the first o...
Read More...
Sep 20, 2019
Roche’s Gazyva receives FDA Breakthrough designation for Lupus nephritis
The US FDA has in a recent move granted Roche’s Gazyva Breakthrough Therapy Designation (BTD) for adults with lupus nephritis. Gazyva (obinutuzumab) is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. Classified as a "monoclonal antibody", Gazyva is a CD20-directed cytolytic antibody. The drug...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
